170 Participants Needed

Accelerated Radiation Therapy for Glioblastoma

Recruiting at 7 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Do I need to stop my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, if you are taking carbidopa/levodopa, you must stop at least 48 hours before an 18F-DOPA-PET scan.

What data supports the effectiveness of Accelerated Hypofractionated Radiation Therapy for glioblastoma?

Research shows that hypofractionated radiation therapy, which involves giving larger doses of radiation over a shorter period, can be effective for glioblastoma, especially in elderly or frail patients. It has been found to be as effective as traditional longer courses of radiation, with the added benefit of a shorter treatment time.12345

Is accelerated radiation therapy safe for humans?

Accelerated radiation therapy, also known as hypofractionated radiation therapy, has been found to be a safe treatment option for glioblastoma patients, including those who are elderly or have other health challenges. While there is a risk of increased toxicity in some cases, studies have shown that most patients tolerate the treatment well, and it is considered a feasible option.14678

How is Accelerated Hypofractionated Radiation Therapy different from other treatments for glioblastoma?

Accelerated Hypofractionated Radiation Therapy is unique because it delivers higher doses of radiation over a shorter period, which can be more convenient for patients and may reduce treatment time without compromising effectiveness or increasing side effects compared to standard radiation therapy.12349

What is the purpose of this trial?

This phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM). The researchers want to learn whether the shorter course treatment is non-inferior (not worse than the standard of care), for patients with GBM. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Short course radiotherapy delivers higher doses of radiation over a shorter period of time and may kill more tumor cells and have fewer side effects.

Research Team

RO

Roman O. Kowalchuk, MD

Principal Investigator

Mayo Clinic in Rochester

WG

William G. Breen, M.D.

Principal Investigator

Mayo Clinic in Rochester

Eligibility Criteria

This trial is for adults over 18 with confirmed glioblastoma, able to complete questionnaires and have an ECOG performance status of 3 or less. Participants must consent in writing, be willing to follow up at the enrolling institution, and have a postoperative tumor size ≤6 cm. Excluded are those with IDH mutation tumors, MRI/18F-DOPA-PET scan issues, certain medication use, not receiving radiation at specified locations, or unwilling to use contraception.

Inclusion Criteria

Ability to complete questionnaire(s) by themselves or with assistance
Provide written informed consent
My diagnosis of glioblastoma has been confirmed through testing.
See 3 more

Exclusion Criteria

Unable to undergo an 18F-DOPA-PET scan
Unable to undergo MRI scans with contrast
I am not using or willing to use birth control.
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Treatment

Patients undergo either short course RT for 5-10 fractions over 1-2 weeks or standard course RT for 15-30 fractions over 3-6 weeks, with concurrent temozolomide administration

1-6 weeks
Multiple visits (in-person) for radiation therapy

Adjuvant Therapy

Patients receive temozolomide on days 1-5 every 28 days for up to 5-6 cycles post-radiation

5-6 months
Monthly visits (in-person or virtual)

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years
Every 2 months for the first year, every 3 months for the second year, every 4 months for the third year, then annually

Treatment Details

Interventions

  • Accelerated Hypofractionated Radiation Therapy
Trial Overview The SAGA Study is testing if short course radiotherapy (RT) can be as effective as standard RT for glioblastoma treatment. It involves higher doses over fewer sessions which may reduce side effects while targeting tumor cells more aggressively than conventional methods.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm A (short course RT)Experimental Treatment9 Interventions
Patients undergo short course RT for 5-10 fractions over 1-2 weeks on study. Patients also receive temozolomide PO on days 1-5 every 28 days during radiation therapy. Starting one month post-radiation, patients continue temozolomide on days 1-5 every 28 days for up to 5 adjuvant cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT with 18-F-DOPA administered IV prior to RT on study, and undergo MRI prior to RT and throughout the trial. Patients may optionally undergo blood sample collection during screening and on the trial.
Group II: Arm B (standard course RT)Active Control9 Interventions
Patients undergo standard course RT for 15-30 fractions over 3-6 weeks on study. Patients also receive temozolomide PO QD concurrently with radiation therapy and for up to 6 adjuvant cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT with 18-F-DOPA administered IV prior to RT on study, and undergo MRI prior to RT and throughout the trial. Patients may optionally undergo blood sample collection during screening and on the trial.

Accelerated Hypofractionated Radiation Therapy is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Accelerated Hypofractionated Radiation Therapy for:
  • Glioblastoma
🇪🇺
Approved in European Union as Accelerated Hypofractionated Radiation Therapy for:
  • Glioblastoma

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials
3,427
Recruited
3,221,000+

Findings from Research

A new survival score was developed for glioblastoma patients based on 10 factors, significantly improving the accuracy of predicting overall survival (OS) compared to previous models, achieving 100% accuracy for predicting death within 12 months.
Key factors for better local control and overall survival included having only one lesion, MGMT promoter methylation, and better performance status, which can help tailor radiotherapy approaches for individual patients.
Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy.Zemskova, O., Yu, NY., Trillenberg, P., et al.[2023]
In a study of 85 adult patients with cerebral glioblastoma, those receiving hypofractionated radiation therapy (5 Gy twice a week) showed better survival rates compared to those receiving conventional radiation therapy, particularly in patients with tumors in the frontal lobe.
The use of misonidazole in the hypofractionated group was associated with improved survival, suggesting it may enhance the effectiveness of this treatment approach.
[Radiation therapy of adult cerebral glioblastoma:].Hayakawa, K., Arai, M., Niibe, H., et al.[2013]
A study involving 158 patients with glioblastoma multiforme (GBM) compared hyperfractionated radiotherapy (hf-rt) and accelerated-hyperfractionated radiotherapy (ahf-rt) to conventional radiotherapy (cf-rt) and found no significant difference in survival rates, with median survival ranging from 7 to 10 months.
The accelerated-hyperfractionated radiotherapy (ahf-rt) reduced treatment time to 4 weeks without compromising survival or increasing toxicity, suggesting it may be a suitable option for patients who cannot undergo more aggressive treatments.
Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.Nieder, C., Nestle, U., Ketter, R., et al.[2022]

References

Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy. [2023]
[Radiation therapy of adult cerebral glioblastoma:]. [2013]
Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme. [2022]
Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience. [2020]
Hypo-fractionated Radiotherapy (HF-RT) Versus Conventionally Fractionated Radiotherapy (CF-RT) for Glioblastoma. [2023]
6.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[Hypofractionated radiotherapy for glioblastoma: changing the radiation treatment paradigm]. [2018]
Accelerated hyperfractionation plus temozolomide in glioblastoma. [2018]
The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. [2019]
Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security